Abstract Library

#4550 The relationship between MEN1 germline mutations and SSTR2 expression in neuroendocrine tumours

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disease characterised by the development of multiglandular parathyroid disease, pituitary tumours, and duodenopancreatic neuroendocrine tumours (NETs). Germline mutations in the tumour suppressor gene MEN1 are the underlying cause. Somatostatin receptor 2 (SSTR2) is commonly expressed by NETs. However, the expression of SSTR2 in patients with MEN1 remains unclear.

Conference:

Presenting Author: Chi Y

Authors: Sun Y, Tan H, Wang H, Shi S, Dong L,

Keywords: multiple endocrine neoplasia type 1, somatostatin receptor 2, neuroendocrine tumour,

#4525 MRI findings of jejunal mesentery neuroendocrine tumour – A case report

Introduction: Neuroendocrine tumours arising from the mesentery are uncommon, with corresponding MRI features infrequently documented in the literature.

Conference:

Presenting Author:

Authors: Guo L, Li Z, Yang H, Dong H, Wang Y,

Keywords: Magnetic Resonance Imaging, Jejunal Mesentery, Neuroendocrine Tumour, Diagnosis,

#4280 Predictive and prognostic nomogram models for liver metastasis in colorectal neuroendocrine neoplasms: A large population study

Introduction: The incidence of patients with colorectal neuroendocrine neoplasms (CRNENs) is continuously increasing. Most patients have distant metastases when diagnosed. Liver metastasis (LM) is the most common type of distant metastasis, and the prognosis is poor once LM occurs. However, there is still a lack of effective models for predicting the risk and prognosis of LM in CRNENs.

Conference:

Presenting Author: Song L

Authors: Lei X, Su Y, Lei R, Zhang D, Liu Z,

Keywords: colorectal neuroendocrine neoplasm, liver metastasis, overall survival, nomogram, SEER, prognostic factor, risk factor,

#4252 Intra-arterial Peptide Receptor Radionuclide Therapy in a Filipino male with predominantly hepatic metastasis in a known primary pancreatic neuroendocrine tumor

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has shown positive clinical outcomes in somatostatin receptor (SSTR) overexpressing positive well-differentiated neuroendocrine tumors in combination with somatostatin analogue therapy. A noted decreased progression-free survivability in the use of PRRT has been noted in larger lesions (>3cm).

Conference:

Presenting Author: Azarraga C

Authors: Azarraga C, Leogardo D, Bandong I, Bautista-Peñalosa P,

Keywords: neuroendocrine, PRRT, intra-arterial, bulky,

#4169 Germline mutation spectrum of neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) are rare and highly heterogeneous tumors. Some specific hereditary syndromes enhance the incidence of NETs, suggesting that germline variation may contribute to neuroendocrine tumorigenesis. However, germline genetic variants in Chinese NET patients remain unclear.

Conference:

Presenting Author:

Authors: Sun Y, Tan H, Dong L, Jiang L, Zhao H,

Keywords: germline mutation, neuroendocrine tumor, genetic,